CASI Pharmaceuticals (CASIF) Preferred Dividend Payments (2022 - 2023)
CASI Pharmaceuticals' (CASIF) quarterly Preferred Dividend Payments came in at $905000.0 in Q4 2023, down 87.49% YoY from $7.2 million in Q4 2022, and up 17.69% on a QoQ basis from $769000.0 in Q3 2023.
CASI Pharmaceuticals (CASIF) Preferred Dividend Payments (2022 - 2023) Analysis & Trends
CASI Pharmaceuticals (CASIF) has 2 years of Preferred Dividend Payments data on file, last reported at $905000.0 in Q4 2023.
- Quarterly Preferred Dividend Payments fell 87.49% year-over-year to $905000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $3.3 million (down 65.45% YoY) and the FY2023 annual result came in at $3.3 million, down 65.45% from the prior year.
- Preferred Dividend Payments advanced to $905000.0 in Q4 2023, from $769000.0 in the prior quarter.
- In the past five years, Preferred Dividend Payments ranged from a high of $7.2 million in Q4 2022 to a low of $613000.0 in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | CASI Pharmaceuticals | 2.65 Mn | -3.76 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 905,000.00 |
| Sep 30, 2023 | 769,000.00 |
| Jun 30, 2023 | 762,000.00 |
| Mar 31, 2023 | 845,000.00 |
| Dec 31, 2022 | 7.23 Mn |
| Sep 30, 2022 | 916,000.00 |
| Jun 30, 2022 | 735,000.00 |
| Mar 31, 2022 | 613,000.00 |